British scientists are leading a global trial for a new pill that could potential help treat prostate cancer.
Early trial test show a third of patients at an advanced state could benefit from the daily pill called PARP-inhibitors. That means it could potentially treat 3,000 men annually.
The drug helps target cancer based on a patient's genetic make-up. If the trial is successful it could be the onset of creating a personalised drug for prostate cancer.
"The work currently being undertaken into PARP inhibitors is leading the way in this field and early studies have shown really encouraging results, " Dr Iain Frame, Director of Research at Prostate Cancer UK, told the Daily Mail.
Adding, "It’s this type of research that can make a real difference to men diagnosed with prostate cancer today, which is why Prostate Cancer UK has kick-started a precision medicine research programme to ensure every man with prostate cancer receives the treatment that will work best for him."
